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To reach the lysosomes, down-regulated receptors such as the
epidermal growth factor receptormust first be sorted into inter-
nal vesicles of late endosomes (multivesicular bodies), a
ubiquitin-dependent event that requires the coordinated func-
tion of the endosome sorting complex required for transport
(ESCRT) proteins. Here we report that CHMP3, an ESCRT-III
complex component, and associatedmolecule of SH3 domain of
STAM (AMSH), a deubiquitinating enzyme, interact with each
other in cells. A dominant-negative version of CHMP3, which
specifically prevents targeting of AMSH to endosomes, inhibits
degradation but not internalization of EGFR, suggesting that
endosomalAMSH is a functional component of themultivesicu-
lar body pathway.
Mono-ubiquitination is a post-translational signal for
sorting internalized membrane proteins into invaginated
membranes within the multivesicular bodies (MVB)3 of late
endosomes (reviewed in Refs. 1 and 2). The sorted proteins
are then transferred to lysosomes, where they are degraded.
This ubiquitin-dependent sorting requires the coordinated
function of a number of molecules that are conserved from
yeast to mammals and collectively referred to as class E Vps
proteins, themselves being either components or associated
proteins of the four known ESCRT complexes (ESCRT-0,
ESCRT-I, ESCRT-II, and ESCRT-III) (reviewed in Ref. 3).
This system is also co-opted by many enveloped viruses,
such as human immunodeficiency virus-1 and Ebola, to bud
from the plasma membrane and thus escape from their host
cells (4–8).
Pathways of ubiquitin-directed protein degradation include
a deubiquitination step for ubiquitin recycling. Of the 17 deu-
biquitinating enzymes present in yeast, Doa4 is the only one
that is functionally linked to the MVB pathway as its deletion
leads to accumulation of several membrane proteins on the
limitingmembrane ofMVB (9, 10). Human cells contain nearly
100 gene products whose sequences indicate a potential for
deubiquitinating activity (11–13). Two of the verified deubiq-
uitinating enzymes, associated molecule of SH3 domain of
STAM (AMSH) and ubiquitin-specific protease Y (UBPY),
appear to function in the mammalian MVB pathway. Despite
their distinct catalytic domains (14, 15), AMSH and UBPY
share several characteristic features. Both proteins bind to the
SH3 domain of STAM, a component of ESCRT-0 (16, 17), and
both strongly colocalize with endosomes when their catalytic
site is made inactive by a single point mutation (15, 18).
Whether these enzymes have critical functions in the MVB
pathway remains to be established as knocking down AMSH
using siRNA results in moderate enhancement, rather than
inhibition, of epidermal growth factor receptor (EGFR) degra-
dation (15, 19). In contrast, knocking down UBPY using siRNA
leads to inhibition of EGFR degradation as well as decreased
levels ofHrs and STAM,which had been shown to be crucial for
EGFR down-regulation (19, 20).
In the course of a search for molecular partners of the
ESCRT-III component CHMP3, the human homologue of
yeast Vps24, we found evidence for a strong interaction with
AMSH.We determined that the N-terminal portion of AMSH,
which does not include the STAM-binding sequence, was nec-
essary for its interaction with CHMP3. Removal of this region
or the STAM-binding sequence did not affect the endosomal
localization of AMSH. Furthermore, expression of a dominant-
negative version of CHMP3, which was not targeted to endo-
somes anddid not affect the endosomal localization of the other
ESCRT-III components but was still capable of interacting with
AMSH, prevented AMSH from targeting to endosomes; under
these conditions, the degradation of activated EGFR was
strongly inhibited, although its internalizationwas normal. As a
complementary approach to confirm the role of AMSH on
EGFR degradation, we used RNA interference to knock down
AMSH and found that although endocytosis of activated EGFR
remained normal, its degradation was also inhibited. From
these observations, we conclude that AMSH is an important
participant inMVB pathway degradation of EGFR and perhaps
other ubiquitinated endocytosed proteins as well.
* This workwas funded by National Institutes of Health Grants GM036548 (to
T. K.) and AI29873 (to H. G. G.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must there-
fore be hereby marked “advertisement” in accordance with 18 U.S.C. Sec-
tion 1734 solely to indicate this fact.
1 A Human Frontier Science Program Long-Term Fellow.
2 To whom correspondence should be addressed: CBR Institute for Biomedi-
cal Research and Dept. of Cell Biology, Harvard Medical School, 200 Long-
wood Ave., Boston, MA 02115. Tel.: 617-278-3140; Fax: 617-278-3131;
E-mail: Kirchhausen@crystal.harvard.edu.
3 The abbreviations used are: MVB, multivesicular body; ESCRT, endosome
sorting complex required for transport; EGF, epidermal growth factor;
EGFR, EGF receptor; AMSH, associated molecule of SH3 domain of STAM;
UBPY, ubiquitin-specific protease Y; siRNA, small interfering RNA; EGFP,
enhanced green fluorescent protein; mRFP, monomeric red fluorescent
protein; GST, glutathione S-transferase; HA, hemagglutinin; MS, mass
spectrometry.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 13, pp. 9805–9812, March 30, 2007
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
MARCH 30, 2007•VOLUME 282•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 9805
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 30, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
EXPERIMENTAL PROCEDURES
Plasmids—Human CHMP3 (BC004419) and CHMP5
(B1914173) cDNAs were purchased from Resgen and Open
Biosystems, respectively. They were sequenced and subcloned
into the pOZ-N vector (a gift from Dr. Y. Shi, Harvard Medical
School), which also encodes the human interleukin-2 receptor.
Human AMSH (BC007682) cDNA was purchased from Open
Biosystems, sequenced, and subcloned into the pEGFP-C1 vec-
tor (Clontech) to create EGFP-AMSH. All deletion mutants of
EGFP-AMSH were generated by PCR mutagenesis. The inter-
nal deletion of EGFP-AMSH (235–239) was introduced by
following the QuikChange site-directed mutagenesis strategy
(Stratagene). The pmRFP-C1 plasmid was constructed by
replacing the EGFP fragment of pEGFP-C1 with two tandem
copies of monomeric red fluorescent protein (mRFP) sequence
(21). Various fragments of CHMP3 were amplified by PCR and
inserted into pGEX-4T or pmRFP-C1 vectors to generate GST
or mRFP fusion proteins. FLAG-Vps4AE228Q and FLAG-
CHMP4A were described previously (6). Human CHMP2A
(BC 002502), CHMP6 (BC 010108), and CHMP3 cDNAs were
purchased from Open Biosystems and subcloned into the pBJ5
vector to create the FLAG-tagged CHMP2A, CHMP3 and
CHMP6 constructs, respectively.
Purification andMass Spectrometry Analysis of CHMP-bind-
ing Proteins—Purification of CHMP3- orCHMP5-binding pro-
teins was carried out as described previously with the following
modifications (22, 23). First, recombinant retroviruses carrying
a bicistronic mRNA containing open reading frames of both
interleukin-2 receptor and FLAG-HA-tagged human CHMP3
or CHMP5 were produced from 293T cells and were used to
transduce HeLa cells. Next, the infected HeLa cells were sorted
using magnetic beads conjugated with anti-interleukin-2
receptor monoclonal antibody, and the resulting stable cell
lines were propagated in suspension. Cytosol was generated
from 4 liters of cells by hypotonic lysis and ultracentrifugation
at 100,000 g for 1 h at 4 °C. Finally, the CHMP3- or CHMP5-
bound proteinswere purified from the cytosol using anti-FLAG
M2 and anti-HA 12CA5monoclonal antibody-conjugated aga-
rose beads (Sigma) sequentially, and bound proteins were frac-
tionated on a 4–20% gradient SDS-PAGE as revealed by silver
staining.
The bands corresponding to the most prominent proteins
and from similar regions of the gel but corresponding to the
DJ-1 (control) sample were excised, digested with trypsin,
and sequenced by tandem mass spectrometry (LC-MS/MS).
The tryptic peptides were separated by reverse-phase using a
microcapillary C18 column (125 m  18 cm) and analyzed
on-line with a hybrid linear ion trap-ion cyclotron resonance
Fourier transform instrument (LTQ-FT, Thermo Finnigan,
San Jose, CA). Full MS2 scans were followed by 10 MS/MS
spectra corresponding to the 10 most abundant ions. MS
spectra were searched using Sequest algorithm, and peptide
matches to the data base were filtered to ensure less than 1%
false-positives hits. The sequences were AVTITDLR, AEEL-
KAELLK, FQETGFFK, EYTEYNEEK, SLKPGALSNSESIP-
TIDGLR, NEFTITHVLIPK, MASIYSEEGNIEHAFILYNK,
YITLFIEK, QQQLEQEQFHAFEMIR, and NMAIQQELE-
KEK for AMSH andTAQEHDKRDPVVAYYCR, LYAMQTG-
MKIDSK, MFLYADNEDR, LYAMQTGMK LMDQLEALKK,
ATYIHNCLK LMDQLEALK, YAGSALQYEDVSTAVQ-
NLQ, and QLGDNEAITQEIVGCAHLENYALK for Lip5,
respectively.
GST Pulldown—Cos7 cells (transfected with FuGENE 6)
were used for the pull-down assays. Cells transiently expressing
the various EGFP-AMSH proteins were lysed with TGH buffer
(50 mM HEPES (pH 7.5), 10% glycerol, 1% Triton X-100, Com-
plete protease inhibitor tablet (Roche Applied Science)). The
soluble fractions were thenmixedwith lysates from Escherichia
coli expressing various GST-CHMP3 proteins and captured
with glutathione-Sepharose beads (Amersham Biosciences)
after a 3-h incubation at 4 °C. Beadswere collected by low speed
centrifugation (1,000 g for 5 min) and washed five times with
phosphate-buffered saline. Beads were boiled, and bound pro-
teins were fractionated by SDS-PAGE. 10% of total input and
100% of the captured AMSH proteins were revealed by West-
ern blot analysis with anti-EGFP (Santa Cruz Biotechnology,
B2) antibody. The amount of GST and GST-CHMP3 fusion
proteins captured by the beads was verified by Coomassie Blue
staining.
Small Interfering RNA—HeLa cells were transfected using
Oligofectamine (Invitrogen) with either one of two different
human AMSH-specific siRNA duplexes (sense 5-UUACAAAU-
CUGCUGUCAUUUU-3 (15) or sense 5-GGUAGCACAACA-
GAAGCAGUU-3 purchased from Dharmacon) 24 h after seed-
ing at30% confluency. The effects of AMSHdepletion on EGFR
internalization and degradation were followed 3 days after trans-
fection with the single cell-based assay described below.
Immunofluorescence Microscopy—Cos7 cells were trans-
fected using FuGENE 6 (Roche Applied Science), fixed with 3%
paraformaldehyde after 10–12 h, and processed for immuno-
fluorescence staining (24). Antibodies were purchased from
Sigma (anti-FLAG M2), Santa Cruz Biotechnology (anti-
EEA1), and Genentech (anti-EGFR 13A9) or received as a gift
from V. Horejsi (anti-CD63). Fluorescently labeled secondary
antibodieswere purchased fromMolecular Probes. Fluorescent
images were obtained with a 100 objective lens using a fluo-
rescent Zeiss microscope configured with a spinning disk con-
focal head or with a 40 objective lens using an upright fluo-
rescent Zeiss microscope including a spherical aberration
correction system under control of SlideBook 4 (Intelligent
Imaging Innovations, Inc) for the degradation and internaliza-
tion experiments.
EGFR Degradation Assay—His6-tagged human EGF was
expressed in E. coli and purified using nickel-nitrilotriacetic
acid chromatography. HeLa cells transfectedwith siRNAoligo-
nucleotides or Cos7 cells transfected with plasmid constructs
encoding for mRFP, mRFP-CHMP3-(151–220), and mRFP-
CHMP3-(151–222) in a 12-well format were serum-starved for
2 h at 72 or 12 h after transfection. The cells were then incu-
bated with 250 ng/ml EGF at 37 °C for 5 min or 2 h followed by
three washes with phosphate-buffered saline (room tempera-
ture) and immediate fixation. Cells were permeabilized with
0.05% saponin dissolved in phosphate-buffered saline including
1% bovine serum albumin and then incubated with the EGFR
antibody 13A9 (dissolved in phosphate-buffered saline and 1%
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bovine serum albumin) followed by a goat anti-mouse Alexa
Fluor-647 secondary antibody. The total fluorescence signal
within each cell was quantified using Slidebook 4 by masking
out the fluorescent signals corrected by the background. 50–60
cells were analyzed for each experimental condition.
EGFR Internalization Assay—HeLa or Cos7 cells were trans-
fected and starved as described for the EGFR degradation assay.
The cells were then incubated with 50 g/ml anti-EGFR anti-
body (13A9) at 37 °C for 10 min in the presence or absence of
250 ng/ml EGF (25). The cells were then fixed, permeabilized,
and stained with Alexa Fluor-594 goat anti-mouse antibody
(25). Image analysis was done following the same procedure
used for the EGFR degradation assay. 30–40 cells were ana-
lyzed for each experimental condition.
RESULTS
AMSH Specifically Interacts with CHMP3—We used a
double epitope tag purification approach combined with
mass spectrometry to identify pro-
teins interacting with CHMP3 and
CHMP5, the human homologues of
yeast Vps24 and Vps60, respectively
(26–28). BothCHMP3 andCHMP5
proteins were tagged at their N ter-
mini with the FLAG and HA
epitopes placed in tandem and sta-
bly expressed in HeLa cells. The
cells were disrupted by hypotonic
lysis followed by a low speed spin to
remove the nuclear fraction. The
analysis was performed on the high
speed supernatant fraction corre-
sponding to the cytosol since most
of CHMP3 and CHMP5 are cytoso-
lic (Fig. 1A). The most abundant
proteins eluted from the FLAG/
HA antibody-conjugated beads had
SDS-PAGE mobilities correspond-
ing to 32–35 kDa; these proteins
were CHMP3 and CHMP5, as con-
firmed by mass spectrometry (Fig.
1B, lanes 3–6). CHMP3 co-purified
with an50 kDa protein, identified
as human AMSH based on 10
matching peptide sequences (Fig.
1B, lanes 3 and 4). AMSH is a
STAM-binding deubiquitinating
enzyme (15, 29). CHMP5 co-puri-
fied with an38 kDa protein, iden-
tified as human Lip5 from the
sequence match of nine peptides
(Fig. 1B, lanes 5 and 6). The interac-
tions of CHMP5-Lip5 and of their
yeast counterparts Vps60-Vta1
were reported recently and thus
were not pursued further (26, 30,
31). As a negative control for speci-
ficity of this purification approach,
we analyzed the eluate from cells stably expressing double-
tagged cytosolic DJ-1 (reviewed in Ref. 32), an oncogene that
links to Parkinson disease and modulates oxidative stress, and
verified that AMSH and Lip5 specifically associate with
CHMP3 and CHMP5, respectively (Fig. 1B, lanes 1 and 2).
The interaction of epitope-tagged CHMP3 with endogenous
AMSHwas subsequently confirmed in a pull-down experiment
using bacterially expressedGST-CHMP3 and cytosolic extracts
from Cos7 cells transiently expressing EGFP-AMSH. As
expected, EGFP-AMSH was detected only in association with
GST-CHMP3 but not with GST alone (Fig. 1C, lanes 1–3 and
13–15). Thus, this assay allowed us to map the binding region
for CHMP3 on AMSH using a series of deletion mutants of
EGFP-AMSH (Fig. 1D). The N-terminal portion of AMSH-(1–
239) bound CHMP3 as efficiently as the full-length AMSH-(1–
424) (Fig. 1C, lanes 4–6). In contrast, smaller fragments (1–127
and 1–102) displayed weaker or undetectable associations (Fig.
1C, lanes 7–12). Truncations of the N-terminal portion of
FIGURE 1. Interaction of AMSH with CHMP3. A, subcellular fractionation of HeLa cells stably expressing
FLAG-HA-DJ-1, FLAG-HA-CHMP3, and FLAG-HA-CHMP5. Cells were hypotonically lysed with TGH buffer and
subjected to centrifugation at 10 kg and 100 kg. Tagged proteins in each fractions were detected by Western
blot using an anti-HA antibody. B, purification andmass spectrometry analysis of CHMP3- andCHMP5-binding
proteins. Cells were lysed, and their cytosolic fractions were subjected to sequential immunoprecipitations
usingFLAGandHAantibody-conjugated resins. Aliquots fromtheproteins eluted fromthebeads, correspond-
ing to the 2% of the first and 10% of the second immunoprecipitations, were fractionated by SDS-PAGE. The
proteins associated with CHMP3 or CHMP5were revealed by silver stain, and the cut bands were subjected to
mass spectrometry sequence analysis. The identified proteins are indicated. C, mapping the CHMP3-binding
region on AMSH by a GST pull-down system. Cos7 cells transiently expressing full length and mutants of
EGFP-AMSH were lysed, and the soluble fraction were mixed with either GST or GST-CHMP3 followed by
incubation with glutathione beads. The beads were boiled, and released proteins were fractionated by SDS-
PAGE and visualized by Western blot (WB) analysis using an anti-EGFP antibody. The lanes show 100% of the
captured EGFP-AMSH proteins and 10% of total input. D, schematic representation of EGFP-AMSH showing
the position of its nuclear localization signal (NLS; 112–127), the STAM-binding motif (SBM; 231–239), and
the JAB1/MPN/Mov34 metalloenzyme motif (JAMM; 323–369) involved in deubiquitination. The drawing
also presents a summary of the pull-down results obtained in this study.
AMSH Is Required for EGFR Degradation
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AMSH (102–424 and 127–424) failed to interact with GST-
CHMP3, indicating that the first 127 residues of AMSH are
essential for association with CHMP3 (Fig. 1C, lanes 19–24).
Moreover, the interaction with STAM was dispensable for the
AMSH-CHMP3 association as the deletion mutant 235–239
lacking the STAM-binding site (16) bound CHMP3 as effi-
ciently as the full-length AMSH (Fig. 1C, lanes 16–18).
The Simultaneous Interactions of AMSH with CHMP3 and
STAM Are Not Essential for Its Endosomal Localization—We
first confirmed that brief expression (10–12 h) in Cos7 cells of
EGFP-AMSH resulted in the same distribution to endosomes,
the plasma membrane, cytosol, and the nucleus (Fig. 2A), as
shown previously in HeLa cells (15). EGFP-AMSH colocal-
ized with early endosomes marked with EEA1, as reported
previously (15), but not to late endosomes labeled with CD63
(Fig. 2A).
We next examined the contribution of association with
STAM and with CHMP3 to the endosomal localization of
AMSH, judging by the extent of colocalization between various
EGFP-AMSH mutants and EEA1 (Fig. 2B). The AMSH frag-
ment lacking the residues required for STAM association
(EGFP-AMSH 235–239) (17) was targeted to early endo-
somes. Likewise, the AMSH fragment lacking the binding site
for CHMP3 (EGFP-AMSH 127–424) was also recruited to
EEA1-labeled endosomes. Taken together, these results con-
firmed that binding to STAMor to CHMP3 is not sufficient for
the endosomal targeting of AMSH (33).
Overexpression of CHMP3-(151–222) Disrupts the Endoso-
mal Localization of AMSH—Having demonstrated that muta-
tions in AMSH preventing its association with either STAM or
CHMP3 were not sufficient to mislocalize AMSH from endo-
somes, we sought another approach to alter the endosomal tar-
geting of AMSH by overexpressing a truncated cytosolic form
of CHMP3 (CHMP3-(151–222)) that still interacts with
AMSH. As a control, we used CHMP3-(151–220) that fails to
interact with AMSH (34).
We first compared the intracellular localization of EGFP-
AMSH in Cos7 cells when co-expressed with CHMP3-(151–
220) or CHMP3-(151–222) fusedwith two copies ofmRFP (Fig.
3A). In the presence of overexpressed mRFP-CHMP3-(151–
220), EGFP-AMSH retained a punctate endosomal pattern,
partially localized to the EEA1 compartment, presumably due
to recruitment by endogenous full-length CHMP3, STAM, and
clathrin. In contrast, in the presence of overexpressed mRFP-
CHMP3-(151–222), EGFP-AMSH lost its punctate pattern and
became cytosolic. Expression of anATPase-defective version of
the mammalian Vps4A, Vps4E228Q, induces the formation of
enlarged hybrid organelles called class E compartments in
which various ESCRT proteins are accumulated as their recy-
cling is dependent on the ATPse activity of Vps4 (35–37).
AMSH was also trapped in the class E compartments in the
presence of CHMP3-(151–220) but remained cytosolic and
excluded from these enlarged organelles in the presence of
CHMP3-(151–222) (Fig. 3B). As an essential control for these
experiments, we demonstrated that overexpression of the
CHMP3 fragments did not affect the endosomal targeting of
other ESCRT-III components. This was done by expression of
either one of the truncated CHMP3 fragments together with
FLAG-tagged full-length CHMP2A, CHMP3, CHMP4A, or
CHMP6 and Vps4E228Q (used here to facilitate visualization).
As shown in the examples in Fig. 3C, targeting of the four
ESCRT-III components to the class E compartment was not
affected. Therefore, CHMP3-(151–222) acted as a dominant-
negative mutant and specifically prevented AMSH from local-
izing to endosomes (Fig. 3A) or to the endosome-originated
class E compartment (Fig. 3B).
Mislocalization or Depletion of AMSH Inhibits EGFR Degra-
dation but Not Internalization—Although the substrate speci-
ficity of AMSH is unknown, its endosomal localization suggests
that it might play a role in the MVB pathway to facilitate the
sorting and degradation of internalized receptors such as
FIGURE 2. AMSH localized to early endosomes. A, Cos7 cells transiently
expressing full-length EGFP-AMSH were fixed and stained with antibodies
specific for EEA1 or CD63 12 h after transfection. B, Cos7 cells transiently
expressing different truncated mutants of EGFP-AMSH were fixed and
stained with anti-EEA1 antibody 12 h after transfection. All images show a
confocal plane corresponding to themiddle sector of the cell. Boxed areas are
shownat highermagnification; arrowheads represent instances of colocaliza-
tion. Scale bar, 20 m.
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EGFR. Thus, we used a single cell imaging assay (26, 38) to
determine whether the degradation of EGFR activated by bind-
ing to its ligand was affected in any way by preventing AMSH
targeting to endosomes by mRFP-CHMP3-(151–222) overex-
pression (Fig. 3A, right panel). In control cells expressingmRFP
only, in which AMSH was properly targeted to endosomes,
EGFR was internalized normally (Fig. 4, right panel), and about
67% of total EGFR was degraded following 2 h of stimulation
with EGF (weak punctate signal of internalized EGFR in Fig. 5A,
right panel and the corresponding quantification in Fig. 5B).
EGFRwas internalized (Fig. 4) and degraded (Fig. 5) to a similar
degree in cells expressing CHMP3-(151–220), which did not
affect the endosomal localization of AMSH (Fig. 3A). In con-
trast, expression of CHMP3-(151–222), which causes the
uncoupling of AMSH from endosomes (Fig. 3A), dramatically
reduced EGFR degradation (Fig. 5), although the internaliza-
tion was not affected (Fig. 4). The amount of EGFR present at
the cell surface prior to EGF treatment was the same in all
conditions (Fig. 4, left panels), showing that expression of the
CHMP3 constructs and themislocalization of AMSHwas of no
consequence for the traffic of EGFR to the cell surface.
It is possible, however, that a mechanism different from
endosomal mistargeting of AMSH is responsible for the effects
just described. To complement the mislocalization studies, we
used an RNA interference-based
approach to examine the effects of
AMSHdepletion on the internaliza-
tion and degradation of activated
EGFR using the single cell imaging
assay (Fig. 6). Degradation (Fig. 6A,
right panels, and 6B, corresponding
quantification) but not internaliza-
tion (Fig. 6A, middle panels) of
EGFRwas strongly inhibited in cells
transfected for 3 days with either
one of two different siRNA oligonu-
cleotides specific for AMSH, These
observations provide further evi-
dence pointing toward an impor-
tant role of AMSH in mediating
EGFR degradation through the
MVB pathway.
DISCUSSION
Our work provides further evi-
dence for an interaction recently
described between the deubiquiti-
nating enzyme AMSH and CHMP3
(39), a component of the ESCRT-III
complex. We also found that failure
to target AMSH to endosomes by
overexpression of a dominant-neg-
ative mutant form of CHMP3,
which can still bind AMSH but does
not localize to endosomes, impairs
the degradation of internalized
EGFR. This observation suggests
that removal of ubiquitin by AMSH
either from components of the ESCRT machinery or from
internalized EGFR is important for receptor down-regulation.
Presumably, AMSH also has a similar role for other membrane
proteins that are degraded through the MVB pathway.
The AMSH-CHMP3 interaction provides a direct link
between a mammalian deubiquitinating enzyme and the
ESCRT-III complex. In contrast, the yeast deubiquitinating
enzyme Doa4 that is functionally associated with the MVB
pathway is linked only indirectly with the ESCRT-III complex.
In that case, the direct contact is between Doa4 and Bro1, a
protein whose association with endosomes depends on the
ESCRT-III protein Snf7 (yeast orthologue of mammalian
CHMP4) (40).
There seem to be at least three ways by which targeting of
AMSH to endosomes is achieved. AMSH can interact with
STAM (17, 29), CHMP3 (Ref. 39 and this work), and clathrin
(39). Some form of coordinated interactions is required, how-
ever, since AMSH is found in endosomes containing clathrin
but does not appear to colocalize with other clathrin-contain-
ing structures at the plasma membrane or within the perinu-
clear region (Ref. 15 and thiswork). Targeting ofAMSH to early
endosomes (Fig. 3A) requires its N-terminal region (Fig. 3B),
which includes binding sites for CHMP3 and for STAM, whose
endosomal localization in turn depends on its association with
FIGURE 3. Overexpression of CHMP3-(151–222) disrupts the endosomal localization of EGFP-AMSH.
A, Cos7 cells were co-transfected with EGFP-AMSH and mRFP-CHMP3-(151–220) or mRFP-CHMP3-(151–222)
using a 1:2 DNA ratio and fixed 10 h after transfection. B, Cos7 cells were triple transfected with EGFP-AMSH,
FLAG-Vps4E228Q, and mRFP-CHMP3-(151–220) or mRFP-CHMP3-(151–222) using a 1:2:2 DNA ratio. At 10 h
after transfection, the cells were fixed and stained with an anti-FLAG antibody. The Vps4E228Q-induced class E
compartment is indicated with arrows. C, Cos7 cells were triple transfected with EGFP-Vps4E228Q, mRFP-
CHMP3-(151–220), or mRFP-CHMP3-(151–222), and FLAG-CHMP2, -3, -4, or -6 using a 1:2:1 DNA ratio. At 10 h
after transfection, the cells were fixed and stained with an anti-FLAG antibody. All images show a confocal
plane corresponding to themiddle section of the cell. Boxed areas are shown at a highermagnification; arrow-
heads represent instances of colocalization. Scale bar, 20 m.
AMSH Is Required for EGFR Degradation
MARCH 30, 2007•VOLUME 282•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 9809
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 30, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Hrs (41). Because the AMSH-STAM or AMSH-CHMP3 inter-
actions alone can still support endosomal targeting, removal of
either one of these interactions cannot be used to study the
effect of endosomal mislocalization on AMSH function (Fig.
2B). Thus, the strategy pursued here of mislocalizing AMSH is
by the squelching effect of overexpressing a truncated mutant
of CHMP3 that can still interact with AMSH but prevents its
endosomal localization. For this approach to be valid, however,
it was essential to show that the endosomal localization of other
ESCRT-III components remains normal upon overexpression
of the CHMP3 fragment (Fig. 3C).
We discovered that overexpression of CHMP3-(151–222),
which interacts with AMSH, acted as a dominant-negative
mutant for the endosomal localization of AMSH, presumably
by forming a complex with AMSH that prevents it from being
targeted to endosomes (Fig. 3A). Furthermore, overexpression
of CHMP3-(151–222) inhibited EGFR degradation without
affecting its internalization (Figs. 4 and 5). In contrast, overex-
pression of the slightly smaller CHMP3-(151–220) had no
detectable effect on the endosomal localization of AMSH or on
EGFR degradation (Figs. 3A and 4, A and B). It is possible that
overexpression of CHMP3-(151–222), but not CHMP3-(151–
220), sequesters other binding partners of CHMP3 besides
FIGURE 4. Overexpression of CHMP3-(151–222) does not affect EGFR
internalization. A, 12 h after transfection with the indicated cDNA con-
structs, Cos7 cells were serum-starved in Dulbecco’s modified Eagle’s
medium for 2 h. The cells were then incubated briefly (10min) with the same
medium supplemented with 50 g/ml anti-EGFR antibody (13A9) in the
absence or presence of 250 ng/ml EGF (25). All of the preceding steps were
carried at 37 °C. This incubation was ended by rapidly washing the cells with
Dulbecco’s modified Eagle’s medium kept at 4 °C followed by an acid wash
step to remove surface-bound antibody applied only to the samples not
treated with EGF. The cells were then fixed, permeabilized, and incubated
with a fluorescently tagged Alexa Fluor-488 secondary antibody (middle and
right panels). The fluorescent haze (middle panels) corresponds to EGFR pres-
ent at the surface of cells not stimulatedwith EGF; the punctate pattern (right
panels) shows the EGFR that internalized in response to EGF treatment. A
similar set of cells, butnot incubatedwithEGF,wasdirectly transferred to4 °C,
stainedwith 5g/ml anti-EGFR antibody, fixed, and stainedwith the second-
ary antibody (left panel); the fluorescence haze in these images reflects the
basal level of EGFR present at the cell surface. Representative images are
shown. Scale bar, 20 m. B, quantification of EGFR internalization from the
immunofluorescent images. 30–40 cells expressing mRFP (white), CHMP3-
(151–220) (light gray), or CHMP3-(151–222) (dark gray) were used for analysis;
the specific fluorescent signal of each cell was determined by removing away
the background signal (masking step, Slidebook 4). Data represent average
signals normalized to the control sample (mRFP) standard error. No statis-
tical differences (Student’s t test) were observed between any of the experi-
mental conditions in the amounts of surface or internalized EGFR.
FIGURE 5. Overexpression of CHMP3-(151–222) inhibits EGFR degrada-
tion. A, Cos7 cells were serum-starved for 2 h and treated with EGF (250
ng/ml) for either 5 min or 2 h at 12 h after transfection. Cells were fixed,
permeabilized, and stained with an anti-EGFR antibody (13A9). Representa-
tive images are shown. Scale bar, 20 m. B, quantification of total EGFR from
the immunofluorescent images. 50–60 transfected cells were masked as in
Fig. 4B, and the total fluorescent intensity of the EGFRwas quantified for each
of the cells using Slidebook4 and expressed as average  standard error of
themean. The statistical significancewas calculatedusing theStudent’s t test.
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AMSH, such as Vps4 (42), which might result in the inhibition
of EGFR degradation. We believe, however, that this is not the
case since Vps4E228Q remained associated with the endosomal
class E compartment it generates when expressed togetherwith
either CHMP3-(151–220) or CHMP3-(151–222) (Fig. 3, B and
C). Thus, endosomal localization of AMSH seems to be impor-
tant for efficient down-regulation of EGFR. It has been estab-
lished that human immunodeficiency virus-1 engages the
ESCRT system for budding and release of the viral particles
from the plasma membrane (4–8). Overexpression of CHMP3
capable of binding AMSH or of an AMSH mutant unable to
remove ubiquitin strongly prevents viral budding, indicating
that like degradation of activated EGFR, these virus-associated
processes also depend on the correct interaction of CHMP3
with AMSH (34, 43).
Our results concerning the role of endosomal AMSH on
EGFR degradation are at variance with the moderate accelera-
tion in receptor degradation previously observed by knocking
down AMSH using siRNA (15, 19). The results from our RNA
interference experiments, using two different siRNAs specific
forAMSH, is a strong inhibition on EGFRdegradation. Perhaps
one explanation for the differences can be ascribed to the longer
post-transfection period (72 versus 48 h) used by us to ensure
maximum depletion of AMSH.
Our observations do not address whether endosomal AMSH
acts directly on cargoes, on components of the ESCRTmachin-
ery, or on both. UBPY is another mammalian STAM-binding
deubiquitinating enzyme targeted to endosomes. It was
recently shown that changes in the expression level of UBPY
but not of AMSH affects the ubiquitination level of EGFR, sug-
gesting that EGFR is not a substrate of AMSH (18). STAM
appears to be a substrate for the deubiquitinating activity of
AMSH, however, as expression of an enzymatically inactive
form of AMSH (D348A) increased the amount of ubiquitinated
STAM and enhanced the association of AMSH with endo-
somes (15, 39). Thus, it remains a possibility that the mislocal-
ization of AMSH attained during our experiments slows down
the deubiquitination of STAM and thereby accelerates its own
degradation and prevents EGFR degradation. Indeed, knocking
down of UBPY expression results in accelerated degradation of
STAM and inhibition of EGFR degradation (20).
In summary, AMSH interacts with a least three distinct com-
ponents of the MVB pathway, STAM, CHMP3, and clathrin.
Proper endosomal localization of AMSH is required for effi-
cient EGFR degradation but not for its internalization. Presum-
ably, othermembrane proteins, also using ubiquitin as a sorting
signal to enter the MVB pathway, are similarly dependent on
AMSH for their degradation.
Acknowledgment—We thank Dr. Yang Shi (HarvardMedical School)
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Addendum—When this manuscript was in preparation, the
CHMP3-AMSH interaction was independently reported by Mc-
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